NCT04026737
Cardiovascular Effects of CART Cell Therapy No drug interventions Not Available Not Available completed NCT05848011
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer treatment 2 recruiting NCT06649838
Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions No drug interventions Not Available Not Available not_yet_recruiting NCT06635954
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications. No drug interventions Not Available Not Available recruiting NCT06608160
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer. No drug interventions Not Available Not Available recruiting NCT06061276
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC treatment Not Available recruiting NCT06510660
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC treatment 2 recruiting NCT06586307
Estimating Lymphocyte Counts from DNA Methylation No drug interventions Not Available Not Available completed NCT06600841
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer treatment 2 not_yet_recruiting NCT06603402
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC No drug interventions treatment 2 recruiting NCT04999943
Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome No drug interventions prevention 1 recruiting NCT04057703
Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia. No drug interventions Not Available Not Available completed NCT04500990
MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study No drug interventions Not Available Not Available unknown_status NCT04329221
Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients prevention 2 not_yet_recruiting NCT05176002
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. treatment 1 / 2 unknown_status NCT04641884
Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy No drug interventions Not Available Not Available unknown_status NCT04558684
Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer No drug interventions treatment 1 / 2 suspended NCT05935579
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer treatment 2 recruiting NCT04642287
Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients treatment 2 not_yet_recruiting NCT06446154
FOLFOX Chemotherapy Plus Fruquintinib and Sintilimab After First-line Treatment in Unresectable Hepatocellular Carcinoma treatment 2 not_yet_recruiting NCT04848454
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy treatment 2 recruiting NCT04670445
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer No drug interventions health_services_research Not Available active_not_recruiting NCT04156698
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma treatment 2 active_not_recruiting NCT06232083
Application of PLDR External Irradiation Combined With Immune Checkpoint Inhibitors in Recurrent Cervical Cancer No drug interventions treatment 1 / 2 recruiting NCT04570683
Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas treatment 0 unknown_status NCT05310383
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer treatment 2 unknown_status NCT06035328
Comparison Efficacy Between Two Different Frequency of Maintenance Dose Oral Immunotherapy No drug interventions treatment Not Available recruiting NCT05807893
Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases treatment 2 / 3 not_yet_recruiting NCT04929093
Novel Dose Adjustment Schedule for Late Injection in SCIT in AR No drug interventions treatment 4 completed NCT04821778
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer treatment 3 recruiting NCT05223088
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer treatment 2 recruiting NCT06241807
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC treatment 2 recruiting NCT05621707
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE) No drug interventions treatment 2 not_yet_recruiting NCT03701607
Effect of Chemotherapy on PD-L1 in NSCLC No drug interventions Not Available Not Available unknown_status NCT04670107
The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy treatment 1 / 2 completed NCT05216237
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer treatment 2 recruiting NCT03003637
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma treatment 1 / 2 completed NCT04372732
Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC No drug interventions Not Available Not Available unknown_status NCT04231552
Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer treatment 1 / 2 unknown_status NCT06165900
Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC treatment 2 recruiting NCT04387500
Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma treatment 2 active_not_recruiting NCT05862259
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies No drug interventions Not Available Not Available recruiting NCT04397575
The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients No drug interventions Not Available Not Available completed NCT04136470
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics Not Available Not Available unknown_status NCT04465942
Immunotherapy in Lung Cancer: Treatment After IO Cessation. Not Available Not Available recruiting NCT06307249
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA treatment 1 recruiting NCT06523049
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy treatment 2 not_yet_recruiting NCT06012318
Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING) No drug interventions Not Available Not Available not_yet_recruiting NCT04286841
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China No drug interventions Not Available Not Available recruiting NCT05375734
Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma treatment 2 recruiting NCT05982834
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC treatment 1 / 2 recruiting NCT06500234
Nutrition Impact on Immunotherapy of Cancer treatment 3 recruiting NCT04441424
Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients treatment Not Available completed NCT06573424
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC Not Available Not Available recruiting NCT06506396
Rehabilitation Needs for Hematologic Cancer Candidate for Hematopoietic Stem Cell Transplantation or CAR T-Cell Therapy No drug interventions Not Available Not Available not_yet_recruiting NCT06542796
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma No drug interventions screening Not Available not_yet_recruiting NCT05515796
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors treatment 2 recruiting NCT06571396
Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma No drug interventions Not Available Not Available recruiting NCT06128863
Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial treatment 2 recruiting NCT03589339
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy treatment 1 recruiting NCT04720339
Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy. No drug interventions other Not Available recruiting NCT04278222
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) treatment 2 recruiting NCT04890522
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC treatment 2 / 3 not_yet_recruiting NCT04552522
Immunological Response After Shrimp Oral Immunotherapy Treatment No drug interventions treatment Not Available active_not_recruiting NCT04711330
Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy No drug interventions Not Available Not Available unknown_status NCT05667857
Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Survivors Treated With Immunotherapy and the Efficacy of Integrative Neurocognitive Remediation Therapy No drug interventions supportive_care Not Available recruiting NCT03695757
Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG treatment 1 / 2 completed NCT03693326
PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities treatment 2 unknown_status NCT06241326
Immunotherapy for Hepatocellular Carcinoma No drug interventions Not Available Not Available recruiting NCT04821765
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer treatment 2 unknown_status NCT05476965
Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma No drug interventions treatment 2 unknown_status NCT03741231
18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy No drug interventions Not Available Not Available completed NCT00720031
Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones No drug interventions treatment 1 / 2 completed NCT05273827
Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium Not Available Not Available completed NCT02692976
Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients No drug interventions treatment 2 completed NCT04188860
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy treatment 2 completed NCT06125262
Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC. No drug interventions Not Available Not Available recruiting NCT06302062
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors treatment 1 recruiting NCT05637580
Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC No drug interventions Not Available Not Available completed NCT04969029
Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations No drug interventions treatment 2 recruiting NCT04291092
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM treatment 2 unknown_status NCT06065592
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms prevention 1 recruiting NCT05225844
An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal treatment 2 unknown_status NCT05817201
Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy treatment 2 / 3 recruiting NCT04688801
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer No drug interventions treatment Not Available recruiting NCT05833672
Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers No drug interventions treatment 2 not_yet_recruiting NCT06014372
Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer treatment 2 recruiting NCT05161572
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer treatment 2 recruiting NCT03198546
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression No drug interventions treatment 1 recruiting NCT05266846
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK treatment 2 recruiting NCT05967910
The Effect of Chronic Stress on Efficacy of ICIs in Esophageal Cancer Patients (STRESS-ESCA Study) No drug interventions Not Available Not Available recruiting NCT06202781
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy No drug interventions Not Available Not Available recruiting NCT06381895
The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder Cancer No drug interventions Not Available Not Available completed NCT04921995
Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma treatment 2 unknown_status NCT03898895
COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer No drug interventions treatment 2 recruiting NCT05273255
Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy other Not Available recruiting NCT05417750
A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors No drug interventions treatment 1 recruiting NCT03888638
The Role of Tumor-associated Macrophages in Colorectal Liver Metastases No drug interventions Not Available Not Available completed NCT04821843
Neoadjuvant Treatment Modalities in Esophageal Cancer treatment 3 recruiting NCT06391190
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer treatment 1 / 2 recruiting NCT04225390
Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy treatment 2 unknown_status NCT05596890
Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients treatment 2 recruiting NCT03765190
Combination of Proton Therapy With Immunotherapy in Multiple Metastases Cancer No drug interventions treatment 1 / 2 unknown_status NCT04225364
Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma treatment 2 completed NCT04389684
Clinical and Psycho-social Impact of COVID-19 Related Confinement on Patients With Digestive Tumors No drug interventions Not Available Not Available completed NCT06356584
Sintilimab Combined With Fruquintinib/Regorafenib ± Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancer treatment 2 recruiting NCT05901584
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC health_services_research 2 recruiting NCT05215379
Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer No drug interventions treatment 2 / 3 recruiting NCT03764787
Combination of Hypofractionated Proton Therapy With Immunotherapy No drug interventions treatment 1 / 2 unknown_status NCT06037733
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy No drug interventions prevention Not Available recruiting NCT03619954
NK Cells Infusion for Advanced Malignancies treatment 1 unknown_status NCT04969354
Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma No drug interventions treatment 1 recruiting NCT06410651
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma treatment 2 recruiting NCT04521153
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma treatment 2 / 3 active_not_recruiting NCT06215677
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer treatment Not Available recruiting NCT04706598
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment treatment 1 / 2 active_not_recruiting NCT06490198
Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin treatment 1 not_yet_recruiting NCT05913583
Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection No drug interventions Not Available Not Available recruiting NCT03357861
Cancer Patients Treated With Immunotherapy in Intensive Care Unit No drug interventions Not Available Not Available completed NCT03070561
Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects No drug interventions other 0 completed NCT04957511
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy No drug interventions Not Available Not Available recruiting NCT04110093
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer treatment 1 / 2 unknown_status NCT06134193
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer treatment 2 not_yet_recruiting NCT03067493
RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial No drug interventions treatment 2 unknown_status NCT05613478
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma treatment 3 recruiting NCT04993378
Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy No drug interventions Not Available Not Available unknown_status NCT06276088
Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy No drug interventions Not Available Not Available recruiting NCT01475188
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy No drug interventions basic_science 4 completed NCT04586088
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure treatment 2 active_not_recruiting NCT03683407
Effect of Chemotherapy on TMB in NSCLC No drug interventions Not Available Not Available unknown_status NCT03042156
Immunotherapy And Palliative Radiotherapy Combined In Patients With Advanced Malignancy No drug interventions Not Available Not Available active_not_recruiting NCT05621356
Monitoring Allergen Immunotherapy in Allergic Rhinitis No drug interventions Not Available Not Available recruiting NCT04895137
mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC treatment 2 recruiting NCT05909137
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer No drug interventions Not Available Not Available not_yet_recruiting NCT04181632
Evaluation of Pain Alleviating Strategies During Allergy Shots No drug interventions other Not Available completed NCT04145232
AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies. Not Available Not Available unknown_status NCT04722952
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML treatment 3 unknown_status NCT03198052
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers No drug interventions treatment 1 recruiting NCT04547452
Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC treatment 2 unknown_status NCT05683652
The Effect of Education and Telephone Follow-up Given to Cancer Patients Receiving Immunotherapy on Symptom Management and Self-care Power No drug interventions prevention Not Available unknown_status NCT05740800
Patient Care Needs and the Decision-Making Experience of Patients With Cancer and Family Caregivers Regarding Immunotherapy: A Qualitative and Quantitative Mixed Methods Study No drug interventions Not Available Not Available completed NCT06567600
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma treatment 2 not_yet_recruiting NCT04539600
Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer treatment 2 unknown_status NCT05354375
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer No drug interventions treatment 1 recruiting NCT03580070
Changes in the Microenvironment of HPV-induced Head and Neck Cancers in West Indies and Metropolitan Population No drug interventions Not Available Not Available completed NCT06413342
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma treatment 2 recruiting NCT04805099
Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease No drug interventions Not Available Not Available completed NCT05334849
Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy No drug interventions Not Available Not Available completed NCT06461936
Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC Not Available Not Available active_not_recruiting NCT06070636
bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma treatment Not Available recruiting NCT04271813
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) treatment 2 completed NCT06065813
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer treatment 2 recruiting NCT05813418
Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment No drug interventions other Not Available recruiting NCT04127318
Low-moderate Intensity Pedaling During Immunotherapy Administration No drug interventions treatment Not Available withdrawn NCT04169841
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment treatment 2 active_not_recruiting NCT04587817
Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors Not Available Not Available unknown_status NCT05719324
Checkpoint Inhibitors in Patients With Solid Tumors: a Retrospective Real-world Study No drug interventions Not Available Not Available recruiting NCT06256224
Toripalimab Combined With Definitive CCRT for LACC Patients treatment Not Available recruiting NCT05775796
Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013) treatment 2 recruiting NCT03066986
Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax) treatment 1 / 2 unknown_status NCT03722186
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies No drug interventions treatment 1 suspended NCT06429839
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients treatment 2 recruiting NCT04405622
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. treatment 2 active_not_recruiting NCT03763630
MAPS & ITEC Cohorts: 6-8 Years Follow-up No drug interventions prevention 2 completed NCT06020430
Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy No drug interventions treatment Not Available recruiting NCT05652530
Clinical Study of the Safety and Efficacy of BCMA CAR-NK No drug interventions treatment 0 recruiting NCT05690048
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) treatment 2 not_yet_recruiting NCT05218148
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma treatment 2 not_yet_recruiting NCT06521866
Toripalimab Combined With Targeted Therapy and Chemotherapy With or Without Radiotherapy as First-Line Treatment for Advanced Colorectal Cancer treatment 2 not_yet_recruiting NCT05024266
Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma treatment 2 unknown_status NCT05311566
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer treatment 2 recruiting NCT05435365
Investigating The Experiences of Patients In Immunotherapy Clinical Trials No drug interventions Not Available Not Available not_yet_recruiting NCT03563482
Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy. No drug interventions diagnostic Not Available unknown_status NCT05652673
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial treatment Not Available recruiting NCT04807127
A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade Not Available Not Available recruiting NCT06120127
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence treatment 2 recruiting NCT06421376
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer No drug interventions treatment 2 recruiting NCT02968394
Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions treatment Not Available unknown_status NCT05657262
Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy Areas No drug interventions health_services_research Not Available completed NCT04037462
Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy treatment 1 / 2 terminated NCT06461780
Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy No drug interventions screening Not Available recruiting NCT05034289
Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy No drug interventions health_services_research Not Available completed NCT05479240
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer treatment 2 not_yet_recruiting NCT06378840
the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer No drug interventions Not Available Not Available recruiting NCT05493267
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB treatment 4 recruiting NCT04169867
Polish Microbiome Map Not Available Not Available unknown_status NCT01256801
Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion No drug interventions Not Available Not Available completed NCT06218901
Association of Psychological Distress in Patients With Lung Cancer No drug interventions Not Available Not Available recruiting NCT04045301
Omalizumab to Accelerate a Symptom-driven Multi-food OIT treatment 2 recruiting NCT05314101
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer treatment 2 unknown_status NCT05136768
Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC) treatment 2 not_yet_recruiting NCT05487469
Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass prevention Not Available unknown_status NCT05304546
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma treatment 2 not_yet_recruiting NCT05321212
Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH) No drug interventions Not Available Not Available completed NCT04682210
Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection treatment 3 not_yet_recruiting NCT05387681
Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric treatment 2 not_yet_recruiting NCT06262581
Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery treatment 2 recruiting NCT05460195
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation treatment 2 recruiting NCT05025514
Retrospective Study of COVID-19 Vaccines in Patients Undergoing Immunotherapy for Cancer. No drug interventions Not Available Not Available unknown_status NCT04807114
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC Not Available Not Available recruiting NCT05202314
Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer treatment Not Available recruiting NCT03971214
PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer treatment 1 unknown_status NCT00540150
Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy No drug interventions treatment 3 completed NCT06313450
De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma No drug interventions treatment Not Available recruiting NCT06125223
PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma No drug interventions Not Available Not Available not_yet_recruiting NCT05669638
A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy No drug interventions Not Available Not Available recruiting NCT06093438
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer treatment 1 / 2 recruiting NCT05825443
Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients treatment 2 recruiting NCT04284332
Phase II Prospective Study of Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC) treatment 2 not_yet_recruiting